ES2198774T3 - Utilizacion de citoquinas y nitrogenos para inhibir respuestas inmunes patologicas. - Google Patents

Utilizacion de citoquinas y nitrogenos para inhibir respuestas inmunes patologicas.

Info

Publication number
ES2198774T3
ES2198774T3 ES98957605T ES98957605T ES2198774T3 ES 2198774 T3 ES2198774 T3 ES 2198774T3 ES 98957605 T ES98957605 T ES 98957605T ES 98957605 T ES98957605 T ES 98957605T ES 2198774 T3 ES2198774 T3 ES 2198774T3
Authority
ES
Spain
Prior art keywords
tgf
cells
production
lse
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98957605T
Other languages
English (en)
Spanish (es)
Inventor
David A. Uty. Of Southern California Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2198774T3 publication Critical patent/ES2198774T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES98957605T 1997-11-05 1998-11-05 Utilizacion de citoquinas y nitrogenos para inhibir respuestas inmunes patologicas. Expired - Lifetime ES2198774T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05
US64507P 1997-11-05

Publications (1)

Publication Number Publication Date
ES2198774T3 true ES2198774T3 (es) 2004-02-01

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98957605T Expired - Lifetime ES2198774T3 (es) 1997-11-05 1998-11-05 Utilizacion de citoquinas y nitrogenos para inhibir respuestas inmunes patologicas.

Country Status (11)

Country Link
US (1) US6228359B1 (https=)
EP (1) EP1028738B1 (https=)
JP (1) JP4309047B2 (https=)
AT (1) ATE238061T1 (https=)
AU (1) AU747767B2 (https=)
CA (1) CA2309115C (https=)
DE (1) DE69813868T2 (https=)
DK (1) DK1028738T3 (https=)
ES (1) ES2198774T3 (https=)
PT (1) PT1028738E (https=)
WO (1) WO1999025366A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999048524A1 (en) 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
ATE404662T1 (de) * 1999-05-05 2008-08-15 Univ Southern California Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
AU769243B2 (en) * 1999-09-01 2004-01-22 University Of Southern California Use of cytokines, cells, and mitogens to inhibit graft versus host disease
DE60141510D1 (de) * 2000-04-11 2010-04-22 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf-beta zur induktion von t-suppressorzellen
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
CA2469800A1 (en) * 2001-12-21 2003-07-24 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
CN108467852A (zh) 2010-04-22 2018-08-31 南加州大学 用于扩增和稳定天然调节性t细胞的方法和组合物
WO2013050529A2 (en) 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
WO2013173076A1 (en) 2012-05-04 2013-11-21 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
AU747767B2 (en) 2002-05-23
DK1028738T3 (da) 2003-08-11
JP2001523443A (ja) 2001-11-27
ATE238061T1 (de) 2003-05-15
AU1382799A (en) 1999-06-07
DE69813868T2 (de) 2004-03-04
JP4309047B2 (ja) 2009-08-05
CA2309115C (en) 2010-10-19
CA2309115A1 (en) 1999-05-27
US6228359B1 (en) 2001-05-08
EP1028738A1 (en) 2000-08-23
PT1028738E (pt) 2003-08-29
EP1028738B1 (en) 2003-04-23
DE69813868D1 (de) 2003-05-28
WO1999025366A1 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
US20130315939A1 (en) Use of Cytokines and Mitogens to Inhibit Pathological Immune Responses
US10611999B2 (en) Methods of expanding and assessing B cells and using expanded B cells to treat disease
ES2198774T3 (es) Utilizacion de citoquinas y nitrogenos para inhibir respuestas inmunes patologicas.
EP1061949B1 (en) Cytokines and mitogens to inhibit graft-versus-host disease
JP2008174564A (ja) 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用
JP4256431B2 (ja) 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用
US20060286067A1 (en) Methods for making and using regulatory T cells
Ohtsuka et al. Cytokine-mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta
Nador et al. The changed balance of regulatory and naive T cells promotes tolerance after TLI and anti-T-cell antibody conditioning
EP1291020A2 (en) Use of cytokines and mitogens to inhibit pathological immune responses
Jang et al. NONCOSTIMULATORY ANTI-CD28 SPECIFIC ANTIBODY INDUCES LONG-TERM HEART ALLOGRAFT SURVIVAL BY SUPPRESSION OF PKCθ-JNK SIGNAL PATHWAY IN ALLOREACTIVE T CELLS.